Interleukin-24 inhibits osteosarcoma cell migration and invasion via the JNK/c-Jun signaling pathways

Zhuo,Baobiao; Shi,Yingchun; Qin,Haihui; Sun,Qingzeng; Li,Zhengwei; Zhang,Fengfei; Wang,Rong; Wang,Xiaodong

doi:10.3892/ol.2017.5990

Interleukin-24 inhibits osteosarcoma cell migration and invasion via the JNK/c-Jun signaling pathways

Authors:
- Baobiao Zhuo
- Yingchun Shi
- Haihui Qin
- Qingzeng Sun
- Zhengwei Li
- Fengfei Zhang
- Rong Wang
- Xiaodong Wang
View Affiliations

Affiliations: Department of Surgery, Xuzhou Children's Hospital, Xuzhou, Jiangsu 221006, P.R. China, Department of Ultrasound, The Affiliated Hospital Xuzhou Medical College, Xuzhou, Jiangsu 221002, P.R. China, Department of Surgery, The Affiliated Children's Hospital of Soochow University, Suzhou, Jiangsu 221006, P.R. China
Published online on: April 5, 2017 https://doi.org/10.3892/ol.2017.5990
Pages: 4505-4511

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Approximately 25% of osteosarcoma patients present with clinically detectable metastatic disease at the time of initial diagnosis. High‑dose chemotherapy and/or surgery for the treatment of primary metastatic osteosarcoma is ineffective, and <20% of patients will survive 5 years from diagnosis. Therefore, the treatment of metastases is critical for the improvement of the prognosis of primary metastatic osteosarcoma patients. We have previously observed that overexpression of interleukin‑24 (IL‑24) inhibits neuroblastoma cell proliferation, migration and invasion in vitro. The present study investigated whether IL‑24 may be a novel agent for osteosarcoma metastasis‑suppressive treatment. It was observed that IL‑24 is able to inhibit migration and invasion in spontaneously metastasizing human 143B osteosarcoma cells via the c‑Jun N‑terminal kinase (JNK)/c‑Jun signaling pathway. IL‑24 was effective in inhibiting JNK and c‑Jun phosphorylation to downregulate matrix metalloproteinase (MMP)‑2 and MMP‑9, which contributed to the suppression of cell migration and invasion. It was concluded that IL‑24 may be a potent agent in the inhibition of highly metastatic 143B osteosarcoma cells, and IL‑24 may have translational potential as an effective therapeutic agent for the treatment of metastatic osteosarcoma.

View Figures

View References

1	Ritter J and Bielack SS: Osteosarcoma. Ann Oncol. 21 Suppl 7:vii320–vii325. 2010. View Article : Google Scholar : PubMed/NCBI
2	Terezhalmy GT, Riley CK and Moore WS: Osteosarcoma. Quintessence Int. 31:592–593. 2000.PubMed/NCBI
3	Moore DD and Luu HH: Osteosarcoma. Cancer Treat Res. 162:65–92. 2014. View Article : Google Scholar : PubMed/NCBI
4	Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M and LaQuaglia M: Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 11:449–453. 1993. View Article : Google Scholar : PubMed/NCBI
5	Kager L, Zoubek A, Pötschger U, Kastner U, Flege S, Kempf-Bielack B, Branscheid D, Kotz R, Salzer-Kuntschik M, Winkelmann W, et al Cooperative German-Austrian-Swiss Osteosarcoma Study Group, : Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol. 21:2011–2018. 2003. View Article : Google Scholar : PubMed/NCBI
6	Rasalkar DD, Chu WC, Lee V, Paunipagar BK, Cheng FW and Li CK: Pulmonary metastases in children with osteosarcoma: Characteristics and impact on patient survival. Pediatr Radiol. 41:227–236. 2011. View Article : Google Scholar : PubMed/NCBI
7	Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, et al: Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
8	Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, et al Children's Oncology Group, : Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol. 26:633–638. 2008. View Article : Google Scholar : PubMed/NCBI
9	Jiang H, Lin JJ, Su ZZ, Goldstein NI and Fisher PB: Subtraction hybridization identifies a novel melanoma differentiation associated gene, mda-7, modulated during human melanoma differentiation, growth and progression. Oncogene. 11:2477–2486. 1995.PubMed/NCBI
10	Caudell EG, Mumm JB, Poindexter N, Ekmekcioglu S, Mhashilkar AM, Yang XH, Retter MW, Hill P, Chada S and Grimm EA: The protein product of the tumor suppressor gene, melanoma differentiation-associated gene 7, exhibits immunostimulatory activity and is designated IL-24. J Immunol. 168:6041–6046. 2002. View Article : Google Scholar : PubMed/NCBI
11	Sauane M, Gopalkrishnan RV, Sarkar D, Su ZZ, Lebedeva IV, Dent P, Pestka S and Fisher PB: MDA-7/IL-24: Novel cancer growth suppressing and apoptosis inducing cytokine. Cytokine Growth Factor Rev. 14:35–51. 2003. View Article : Google Scholar : PubMed/NCBI
12	Whitaker EL, Filippov VA and Duerksen-Hughes PJ: Interleukin 24: Mechanisms and therapeutic potential of an anti-cancer gene. Cytokine Growth Factor Rev. 23:323–331. 2012. View Article : Google Scholar : PubMed/NCBI
13	Su ZZ, Lebedeva IV, Sarkar D, Emdad L, Gupta P, Kitada S, Dent P, Reed JC and Fisher PB: Ionizing radiation enhances therapeutic activity of mda-7/IL-24: Overcoming radiation- and mda-7/IL-24-resistance in prostate cancer cells overexpressing the antiapoptotic proteins bcl-xL or bcl-2. Oncogene. 25:2339–2348. 2006. View Article : Google Scholar : PubMed/NCBI
14	Dent P, Yacoub A, Hamed HA, Park MA, Dash R, Bhutia SK, Sarkar D, Wang XY, Gupta P, Emdad L, et al: The development of MDA-7/IL-24 as a cancer therapeutic. Pharmacol Ther. 128:375–384. 2010. View Article : Google Scholar : PubMed/NCBI
15	Zhuo B, Wang R, Zhang H, Qin H, Yin Y and Shi Y: Interleukin-24 inhibits cell migration and invasion in the neuroblastoma cell line SH-SY5Y. Oncol Rep. 30:2749–2754. 2013.PubMed/NCBI
16	Zhuo B, Wang R, Yin Y, Zhang H, Ma T, Liu F, Cao H and Shi Y: Adenovirus arming human IL-24 inhibits neuroblastoma cell proliferation in vitro and xenograft tumor growth in vivo. Tumour Biol. 34:2419–2426. 2013. View Article : Google Scholar : PubMed/NCBI
17	Ramesh R, Ito I, Gopalan B, Saito Y, Mhashilkar AM and Chada S: Ectopic production of MDA-7/IL-24 inhibits invasion and migration of human lung cancer cells. Mol Ther. 9:510–518. 2004. View Article : Google Scholar : PubMed/NCBI
18	Shi H, Wei LL, Yuan CF, Yang JX, Yi FP, Ma YP and Song FZ: Melanoma differentiation-associated gene-7/interleukin 24 inhibits invasion and migration of human cervical cancer cells in vitro. Saudi Med J. 28:1671–1675. 2007.PubMed/NCBI
19	Xiao CW, Xue XB, Zhang H, Gao W, Yu Y, Chen K, Zheng JW and Wang CJ: Oncolytic adenovirus-mediated MDA-7/IL-24 overexpression enhances antitumor activity in hepatocellular carcinoma cell lines. Hepatobiliary Pancreat Dis Int. 9:615–621. 2010.PubMed/NCBI
20	Fisher PB, Sarkar D, Lebedeva IV, Emdad L, Gupta P, Sauane M, Su ZZ, Grant S, Dent P, Curiel DT, et al: Melanoma differentiation associated gene-7/interleukin-24 (mda-7/IL-24): Novel gene therapeutic for metastatic melanoma. Toxicol Appl Pharmacol. 224:300–307. 2007. View Article : Google Scholar : PubMed/NCBI
21	Bjørnland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O and Maelandsmo GM: Matrix metalloproteinases participate in osteosarcoma invasion. J Surg Res. 127:151–156. 2005. View Article : Google Scholar : PubMed/NCBI
22	Yamaguchi H, Wyckoff J and Condeelis J: Cell migration in tumors. Curr Opin Cell Biol. 17:559–564. 2005. View Article : Google Scholar : PubMed/NCBI
23	Carragher NO and Frame MC: Focal adhesion and actin dynamics: A place where kinases and proteases meet to promote invasion. Trends Cell Biol. 14:241–249. 2004. View Article : Google Scholar : PubMed/NCBI
24	Pickup MW, Mouw JK and Weaver VM: The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 15:1243–1253. 2014. View Article : Google Scholar : PubMed/NCBI
25	Wolf K, Wu YI, Liu Y, Geiger J, Tam E, Overall C, Stack MS and Friedl P: Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol. 9:893–904. 2007. View Article : Google Scholar : PubMed/NCBI
26	Wolf K and Friedl P: Extracellular matrix determinants of proteolytic and non-proteolytic cell migration. Trends Cell Biol. 21:736–744. 2011. View Article : Google Scholar : PubMed/NCBI
27	McCawley LJ and Matrisian LM: Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol Med Today. 6:149–156. 2000. View Article : Google Scholar : PubMed/NCBI
28	Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: Regulators of the tumor microenvironment. Cell. 141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
29	Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM and Helman LJ: The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 10:182–186. 2004. View Article : Google Scholar : PubMed/NCBI
30	Huang CY, Lee CY, Chen MY, Yang WH, Chen YH, Chang CH, Hsu HC, Fong YC and Tang CH: Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways. J Cell Physiol. 221:204–212. 2009. View Article : Google Scholar : PubMed/NCBI
31	Iiizumi M, Bandyopadhyay S, Pai SK, Watabe M, Hirota S, Hosobe S, Tsukada T, Miura K, Saito K, Furuta E, et al: RhoC promotes metastasis via activation of the Pyk2 pathway in prostate cancer. Cancer Res. 68:7613–7620. 2008. View Article : Google Scholar : PubMed/NCBI
32	Huang Q, Lan F, Wang X, Yu Y, Ouyang X, Zheng F, Han J, Lin Y, Xie Y, Xie F, et al: IL-1β-induced activation of p38 promotes metastasis in gastric adenocarcinoma via upregulation of AP-1/c-fos, MMP2 and MMP9. Mol Cancer. 13:182014. View Article : Google Scholar : PubMed/NCBI
33	Moon SK, Kim HM, Lee YC and Kim CH: Disialoganglioside (GD3) synthase gene expression suppresses vascular smooth muscle cell responses via the inhibition of ERK1/2 phosphorylation, cell cycle progression, and matrix metalloproteinase-9 expression. J Biol Chem. 279:33063–33070. 2004. View Article : Google Scholar : PubMed/NCBI
34	Gao X, Balan V, Tai G and Raz A: Galectin-3 induces cell migration via a calcium-sensitive MAPK/ERK1/2 pathway. Oncotarget. 5:2077–2084. 2014. View Article : Google Scholar : PubMed/NCBI
35	Hsieh YS, Chu SC, Yang SF, Chen PN, Liu YC and Lu KH: Silibinin suppresses human osteosarcoma MG-63 cell invasion by inhibiting the ERK-dependent c-Jun/AP-1 induction of MMP-2. Carcinogenesis. 28:977–987. 2007. View Article : Google Scholar : PubMed/NCBI
36	Fromigué O, Hamidouche Z and Marie PJ: Statin-induced inhibition of 3-hydroxy-3-methyl glutaryl coenzyme a reductase sensitizes human osteosarcoma cells to anticancer drugs. J Pharmacol Exp Ther. 325:595–600. 2008. View Article : Google Scholar : PubMed/NCBI